
zzso is an oral zzso inhibitor that zzso zzso zzso zzso and zzso zzso zzso involved in tumor growth and zzso It has demonstrated zzso and clinical activity in several tumor zzso zzso 400 zzso twice daily zzso has been approved in several countries worldwide for the treatment of zzso cell zzso This review summarizes key safety, zzso and efficacy data from four phase I, zzso zzso studies with zzso in patients with advanced zzso solid tumors zzso zzso zzso These trials followed different treatment regimens (7 days zzso days off, zzso zzso zzso 21 days zzso days off, zzso zzso zzso 28 days zzso days off, zzso zzso zzso or continuous zzso zzso zzso zzso to establish the optimum dosing zzso zzso was generally well zzso most adverse events were mild to moderate in severity up to the defined zzso dose of 400 zzso twice daily zzso The most frequently reported drug-related adverse events at any grade included fatigue zzso anorexia zzso zzso zzso zzso zzso and zzso skin reaction zzso zzso demonstrated preliminary zzso activity, particularly among patients with zzso cell zzso or zzso zzso overall, two of 137 zzso patients achieved partial responses and 38 zzso had stable zzso Although there was high zzso zzso in plasma zzso across these studies, this was not associated with an increased zzso or severity of zzso zzso studies suggest that zzso zzso zzso zzso in tumor cells or peripheral blood zzso may be a useful zzso for measuring and, ultimately, predicting the effects of zzso Based on these findings, continuous daily 400 zzso bid zzso was chosen as the optimal regimen for phase zzso zzso Trials are ongoing in zzso cell zzso zzso zzso melanoma, and zzso cell lung zzso 

